Greek English Arabic Arabic Romanian Russian
AABB Accredited
Lifeline
Tuesday, 28 March 2017
The first and largest family Umbilical Cord Blood and Tissue Bank in Cyprus.


Quick Search:
 
Enrol with Lifeline Lifeline Advantages Video Center Contact Lifeline Brochure
About Us
Umbilical Cord Blood
Umbilical Cord Tissue
Regenerative Medicine
Lifeline Service
Stem Cell Collection
Laboratory Facilities
Lifeline News
Media and Video News
Media News
Video Center
Regulations & Directives
FAQs
Contact Us
AABB Accredited
European Business Awards 2014-15
Lifeline, Winner of the Cyprus Innovation Award - Services Sector 2010

Transplanted human umbilical cord blood cells improved heart function in rat model of MI



Putnam Valley, NY. (Mar. 6, 2014) – When human umbilical cord blood cells were transplanted into rats that had undergone a simulated myocardial infarction (MI), researchers investigating the long term effects of the transplantation found that left ventricular (LV) heart function in the treated rats was improved over those that did not get the stem cells. The animals were maintained without immunosuppressive therapy.

 

The study will be published in a future issue of Cell Transplantation but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct0860Chen.

 

"Myocardial infarction induced by coronary artery disease is one of the major causes of heart attack," said study co-author Dr. Jianyi Zhang of the University of Minnesota Health Science Center. "Because of the loss of viable myocardium after an MI, the heart works under elevated wall stress, which results in progressive myocardial hypertrophy and left ventricular dilation that leads to heart failure. We investigated the long term effects of stem cell therapy using human non-hematopoietic umbilical cord blood stem cells (nh-UCBCs). These cells have previously exhibited neuro-restorative effects in a rodent model of ischemic brain injury in terms of improved LV function and myocardial fiber structure, the three-dimensional architecture of which make the heart an efficient pump."

 

According to the authors, stem cell therapy for myocardial repair has been investigated extensively for the last decade, with researchers using a variety of different animal models, delivery modes, cells types and doses, all with varying levels of LV functional response. They also note that the underlying mechanisms for improvement are "poorly understood," and that the overall regeneration of muscle cells is "low."

 

To investigate the heart's remodeling processes and to characterize alterations in the cardiac fiber architecture, the research team used diffusion tensor MRI (DTMRI), used previously to study myofiber structure in both humans and animals.

 

While most previous studies have been focused on the short term effects of UCBCs, their study on long term effects not only demonstrated evidence of significantly improved heart function in the treated rats, but also showed evidence of delay and prevention in terms of myocardial fiber structural remodeling, alterations that could have resulted in heart failure.

 

When compared to the age-matched but untreated rat hearts with MI, the regional myocardial function of nh-UCBC-treated hearts was significantly improved and the preserved myocardial fiber structure may have served as an "underlying mechanism for the observed function improvements."

 

"Our data demonstrate that nh-UCBC treatment preserves myocardial fiber structure that supports the improved LV regional and chamber function," concluded the researchers.

 

"This study provides evidence that UCBCs could be a potential therapy with long term benefits for MI" said Dr. Amit N. Patel, director of cardiovascular regenerative medicine at the University of Utah and section editor for Cell Transplantation. "Preservation of the myocardial fiber structure is an important step towards finding an effective therapy for MIs"

 

Source: Cell Transplantation Center of Excellence for Aging and Brain Repair

 http://www.sciencecodex.com/ 

 

 

LFLN REF. 27.03.14 P.34

Enrol with Lifeline
Media and Video News
»AIDS

»Anemias

»Autism

»Bone Disorders

»Cancer

»Cerebral Palsy

»Cord Blood News

»Diabetes

»Ex-Vivo Expansion

»Heart Repair

»Immunodeficiencies

»Leukemias

»Mesenchymal Cells

»Multiple Sclerosis

»Parkinson's

»Regenerative Medicine

»Spinal Cord Injuries

»Stem Cell Harvest for the Future

»Stroke/Brain Injury

Top  |  Back  |  Easy Print  |  Advanced Search  |  Contact Us  |  Home
Participation in External Quality Control Schemes
UK NEQAS International Quality Expertise Labquality AABB Accredited
Lifeline © Copyright © C.B.B. Lifeline Biotech Ltd  |  Disclaimer  |  Terms of Use Design & Development: Crucial Services Ltd